Invention Grant
US08501168B2 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods
有权
细胞系,包含它们用于治疗黑素瘤的组合物,制备组合物的程序和治疗方法
- Patent Title: Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods
- Patent Title (中): 细胞系,包含它们用于治疗黑素瘤的组合物,制备组合物的程序和治疗方法
-
Application No.: US12450721Application Date: 2008-04-11
-
Publication No.: US08501168B2Publication Date: 2013-08-06
- Inventor: José Mordoh , María Marcela Barrio , Erika María Von Euw
- Applicant: José Mordoh , María Marcela Barrio , Erika María Von Euw
- Applicant Address: AR Buenos Aires
- Assignee: Consejo Nacional de Investigaciones Cientificas y Tecnicas (Conicet)
- Current Assignee: Consejo Nacional de Investigaciones Cientificas y Tecnicas (Conicet)
- Current Assignee Address: AR Buenos Aires
- Agency: Nath, Goldberg & Meyer
- Agent Tanya E. Harkins
- Priority: ARP20070101520 20070411
- International Application: PCT/IB2008/051385 WO 20080411
- International Announcement: WO2008/126039 WO 20081023
- Main IPC: A61K39/00
- IPC: A61K39/00 ; C12N5/0784 ; C12N5/09

Abstract:
Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods. More particularly, the invention relates to diverse human melanoma cell lines for the treatment of malignant diseases, wherein the cell lines are: (a) Mel-XY1 (deposited at German Collection of Microorganisms and Cell Cultures DSMZ under access number DSM ACC2830), (b) Mel-XY2 (deposited at German Collection of Microorganisms and Cell Cultures DSMZ under access number DSM ACC2831), (c) Mel-XY3 (deposited at German Collection of Microorganisms and Cell Cultures DSMZ under access number DSM ACC2832), (d) Mel-XX4 (deposited at German Collection of Microorganisms and Cell Cultures DSMZ under access number DSM ACC2829), or (e) sub-populations thereof. The cell lines may be irradiated, thus obtaining populations with apoptotic phenotype, and populations with necrotic phenotype of such lines. The compositions may comprise adjuvants and/or immuno-modifiers, and/or autologous dendritic cells.
Public/Granted literature
Information query